FDA approves AI-powered cardiac MRI technology

HeartVista—a company focused on AI-powered MRI solutions—has received 510(k) clearance from the FDA for its AI-assisted One Click MRI software, the first system of its kind, according to a company announcement.

The Los Altos, California-based company’s cardiac system automatically recommends cardiac views with one click, enabling more efficient and cost-effective cardiac MRI exams.

“Patients across the country now have access to the only AI-guided cardiac MRI exam, which will deliver continuous imaging via an automated process, minimize errors and simplify scan operation,” Raymond Kwong, MPH, director of cardiac magnetic resonance imaging at Brigham and Women’s Hospital, said in the announcement.

Kwong also noted the outcomes of the recent MR-INFORM study published in the New England Journal of Medicine that found non-invasive myocardial perfusion cardiac MRI performed as well as invasive FFR—once the “gold standard” to treat patients with stable chest pain.

“Our AI solution generates definitive, accurate and actionable real-time data for cardiologists,” Kwong added. “We believe it will elevate the standard of care for cardiac imaging, enhance patient experience and access, and improve patient outcomes.”

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.